Evidence map›Paper›PMID 33584075›Full record

ArticleWorld journal of gastroenterology2021

Vedolizumab in Crohn's disease with rectal fistulas and presacral abscess: A case report.

Heng Yeh, Chia-Jung Kuo, Ren-Chin Wu, Chien-Ming Chen, Wen-Sy Tsai, Ming-Yao Su, Cheng-Tang Chiu, Puo-Hsien Le

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Heng YehSchool of Medicine, Chang Gung University, Taoyuan City 333323, Taiwan.
Chia-Jung KuoDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
Ren-Chin WuDepartment of Pathology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
Chien-Ming ChenDepartment of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
Wen-Sy TsaiDepartment of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
Ming-Yao SuTaiwan Association of the Study of Small Intestine Disease, Taoyuan 333, Taiwan.
Cheng-Tang ChiuDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.
Puo-Hsien LeDepartment of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan. puohsien@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFistula and intraabdominal fistula are common complications of Crohn's disease (CD), but complex rectal fistula with abscess formation is rare. Tumor necrosis factor antagonists combined with percutaneous drainage or surgical intervention is optimal treatment for fistulizing CD with intraabdominal abscess. There is no study show the efficacy of vedolizumab in such complicated condition. CASE SUMMARY: A 47-year-old man has decompensated liver cirrhosis, child B. He suffered from abdominal pain, bloody diarrhea, fever, and body weight loss. CD with rectoprostatic fistula, rectopresacral fistula, pre-sacral abscess and cyto-megalovirus (CMV) infection were noted. He received antibiotics, anti-viral therapy, transverse colostomy and vedolizumab treatment. Six months later, he had deep remission and complete fistula tracts closure.

conclusionEarly vedolizumab and stool diversion are effective and safe in treating CD with complex rectal fistula with abscess formation.

Indexed as

Crohn DiseaseRectal FistulaAbscessAntibodies, Monoclonal, HumanizedChildHumansMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedvedolizumabCase reportCrohn's diseasePre-sacral abscessRectal pre-sacral fistulaRectoprostatic fistulaVedolizumab

Identifiers

PMID33584075
PMCPMC7856844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.